Baltimore, MD, United States of America

Paul Madepogu

This inventor holds 4 USPTO granted patents, plus 2 CIPO patents and 3 EPO patents. Top assignee: Becton Dickinson and Company Limited. Active years: 2017-2020.


% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Paul Madepogu: Innovator in Nucleic Acid Testing

Introduction

Paul Madepogu is a distinguished inventor based in Baltimore, MD (US). He has made significant contributions to the field of nucleic acid testing, holding a total of 4 patents. His work focuses on developing methods and compositions that enhance the detection of specific genetic materials.

Latest Patents

Among his latest patents, Paul Madepogu has disclosed innovative methods for the detection of nucleic acids. These methods utilize nucleic acid-based testing techniques that employ primers and/or probes targeting the opcA gene region. Additionally, he has developed internal control nucleic acids that facilitate amplification processes, including quantitative nucleic acid amplification.

Career Highlights

Paul Madepogu is currently associated with Becton Dickinson and Company, a leading global medical technology company. His role at Becton Dickinson allows him to apply his expertise in nucleic acid testing to develop advanced diagnostic solutions.

Collaborations

Throughout his career, Paul has collaborated with notable colleagues, including Keith Edward Thornton and Danielle Koffenberger. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

In summary, Paul Madepogu is a prominent inventor whose work in nucleic acid testing has led to significant advancements in the field. His contributions continue to impact medical diagnostics and research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…